EXPERIENCE OF ADMINISTRATION OF CANAKINUMAB, AN INTERLEUKIN 1β INHIBITOR, IN A PATIENT WITH CHRONIC TOPHACACEOUS GOUT
This article reports a clinical case of administration of canakinumab (Ilaris®), an interleukin-1β inhibitor, in a patient with chronic tophacaceous gout resistant to therapy with nonsteroidal anti-inflammatory drugs, glucocorticoids, and colchicine. The results show a good and long-term clinical ef...
Saved in:
| Main Authors: | Maksim Sergeyevna Eliseev, O V Zhelyabin, V G Barskova, E L Nasonov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2014-03-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/1365 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Assessment of cardiovascular risk from the use of an interleukin-1 inhibitor in patients with severe tophaceous gout
by: M. S. Eliseev, et al.
Published: (2016-03-01) -
Experience with Uralyt-U citralite used in patients with gout and nephrolithiasis
by: Maksim Sergeyevich Eliseyev, et al.
Published: (2012-09-01) -
USE OF URISAN IN PATIENTS WITH GOUT
by: L A Knyazeva, et al.
Published: (2010-03-01) -
Risk factors for type 2 diabetes mellitus in patients with gout: results from a prospective study
by: O. V. Zhelyabina, et al.
Published: (2022-02-01) -
Comments on the updated recommendations of the American College of Rheumatology (ACR) for the treatment of gout. Lifestyle (part 2)
by: M. S. Eliseev
Published: (2021-04-01)